Return to TA204 Overview

Denosumab for the prevention of osteoporotic fractures in postmenopausal women [TA204]

Measuring the use of this guidance

Recommendation: 1.2

Denosumab is recommended as a treatment option for the secondary prevention of osteoporotic fragility fractures only in postmenopausal women at increased risk of fractures who are unable to comply with the special instructions for administering alendronate and either risedronate or etidronate, or have an intolerance of, or a contraindication to, those treatments.

What was measured: The proportion of fracture liaison services in England that could directly recommend or prescribe denosumab.
Data collection end: December 2014
56%
Area covered: England
Source: Royal College of Physicians. Fracture Liaison Service Database (FLS-DB) Facilities audit

What was measured: Proportion of cases (both men and women) where denosumab was prescribed for the secondary prevention of fragility fractures.
Data collection end: December 2016
3%
Area covered: England and Wales
Source: Royal College of Physicians. Fracture Liaison Service Database (FLS-DB) clinical audit



 Return to TA204 Overview